Anti-Amyloid Beta (25-35)

Amyloid Beta (25-35) is increasingly recognized as a significant player in the pathogenesis of neurological disorders, particularly in Alzheimer’s disease. Anti-AMyloid Beta (25-35) is an antibody against the Amyloid Beta (25-35) protein.  

In contrast to Amyloid Beta (1-42), which is the Amyloid Beta peptide most prone to forming disease-promoting aggregations, AMyloid Beta (25-35) is thought to be more neurotoxic.  

This article aims to explore the crucial role of Anti-Amyloid Beta (25-35) in neurological health, providing an in-depth analysis of its characteristics, functions, and implications in disease pathology. 

The presence and levels of Amyloid Beta (25-35) in biological systems can shed light on pathological changes in the brain, offering insights into the mechanisms driving neurodegeneration.

What is the Amyloid Beta Protein?

Definition of the Amyloid Beta Protein and its Connection to Alzheimer's Disease  [3.]

Amyloid beta (Aβ) peptides are derived from the amyloid precursor protein (APP), an integral membrane protein expressed in various tissues, particularly in neuronal synapses.  Amyloid beta peptides are central to Alzheimer's disease (AD) pathogenesis.

Aβ peptides, ranging from 37 to 49 amino acids, are generated through the amyloidogenic pathway via enzymatic cleavage which results in the formation of amyloid plaques characteristic of AD.  These enzymes represent a potential therapeutic target for AD.

The normal production of amyloid beta proteins involves the cleavage of the amyloid precursor protein (APP) by α-secretase or β-secretase, followed by γ-secretase cleavage, resulting in the formation of soluble Aβ peptides.  Normally, the amyloid beta proteins are cleared from the brain.  

In contrast, pathological production of Aβ occurs when there is an imbalance in the processing of APP, leading to increased production or reduced clearance of Aβ peptides. 

This imbalance may result from genetic or environmental factors, increasing age, vascular dysfunction, inflammation, or alterations in the amyloid beta clearance pathway, leading to the accumulation of Aβ peptides and their aggregation into insoluble fibrils.  [6.]

The function of amyloid beta in healthy cells is not well-known, although its propensity for accumulating metal ions including zinc and copper hints at its role in metal sequestration.  [5.]

The aggregation of these amyloid beta (Aβ) peptides into fibrils is central to Alzheimer's disease (AD) pathogenesis, though the exact correlation between amyloid plaques and neuronal loss remains unclear.  Specifically, the amyloid plaques are composed of these amyloid beta fibrils.  

What is Amyloid Beta (25-35)?  [4., 7., 9.]

Amyloid beta (25-35) is one type of amyloid beta peptide, and a peptide implicated in Alzheimer's disease pathology. 

While the Amyloid Beta (1-42) peptide is significant due to its increased tendency to aggregate, the Amyloid Beta (25-35) peptide is known for its increased neurotoxicity.  

Amyloid beta 25-35 is an undecapeptide fragment derived from the longer amyloid beta (Aβ) peptides Aβ(1–40/42), which are associated with Alzheimer's disease (AD). 

Aβ(25–35) exhibits a molecular structure that closely resembles the fibril-forming properties and neurotoxicity of its parent peptides. Its sequence comprises 11 amino acids, with residues 25 to 35 of the full Amyloid Beta sequence. 

Despite its shorter length, Aβ(25–35) retains the ability to form amyloid fibrils although it is also known for its neurotoxicity in the pathogenesis of AD.  Its shorter chain length may allow it to aggregate more rapidly, potentially contributing to the formation of plaques and neuronal damage in the brain.

What is Anti-Amyloid Beta (25-35)?

Definition of Anti-Amyloid Beta (25-35) Antibody

The antibody anti-amyloid beta 25-35 is a monoclonal antibody designed to specifically target and bind to the amyloid beta 25-35 (Aβ(25–35)) peptide, an important fragment derived from the amyloid beta protein associated with Alzheimer's disease (AD). 

This antibody is engineered to recognize and selectively bind to the Aβ(25–35) peptide, thereby modulating its aggregation and potentially reducing the formation of toxic amyloid fibrils.

 By targeting this specific peptide sequence, the antibody aims to interfere with the pathological processes underlying AD, such as amyloid plaque formation and neuronal toxicity; its effects may also extend to Amyloid beta 1-42.  [12.]

What Does the Anti-Amyloid Beta (25-35) Antibody Do?  [11.]

The anti-amyloid beta 25-35 antibody is specifically engineered to target the Aβ(25–35) peptide, a fragment implicated in Alzheimer's disease (AD).

By selectively binding to Aβ(25–35), the antibody aims to disrupt its aggregation, potentially impeding the formation of toxic amyloid fibrils, a hallmark of AD pathology. 

This targeted intervention attempts to mitigate the progression of AD by addressing early stages of amyloid aggregation. Moreover, antibody fragments offer promise in AD therapy due to their smaller size, enhanced blood-brain barrier penetration, and reduced risk of adverse effects associated with full antibodies. 

Lab Testing for Amyloid Beta (25-35) Peptides

Amyloid Beta (25-35) peptides are not commonly assessed.  Instead, the presence of amyloid beta (1-42) is typically assessed in cerebrospinal fluid and/or plasma for diagnosing and monitoring Alzheimer’s disease. 

Indications for Testing

Lab testing for Amyloid Beta (1-42) peptides is primarily indicated in the evaluation of patients suspected of having Alzheimer’s disease or other forms of dementia. 

Techniques and Methodologies for Detection

The detection of Amyloid Beta (1-42) typically involves analyzing cerebrospinal fluid (CSF) samples for the presence of the amyloid-beta 1-42 peptides as well as other markers of AD pathogenesis.  [2.]

It is also available as a blood test, which commonly assesses the ratio of amyloid Beta (1-42) to amyloid Beta (1-40) peptide levels.  [1.]  This is intended to be an adjunctive test in the diagnosis of AD along with cognitive performance tests and PET neuroimaging scans.  

Biomarkers Related to Amyloid Beta (1-42) in Alzheimer's Disease and Neurodegeneration

Amyloid Beta (1-42) testing is highly specialized, and testing for Amyloid Beta (25-35) is not commonly available.  

In contrast, genetic testing may provide insight into individuals with greater risk of developing Alzheimer’s disease and provide opportunities to implement diet and lifestyle strategies to protect neurological and cognitive health.  

Genetic Testing to Identify Increased Risk of Alzheimer’s Disease 

The APOE genetic test for Alzheimer's disease is clinically valuable in assessing an individual's risk of developing the condition. 

Specifically, this test identifies variations in the apolipoprotein E (APOE) gene, with the ε4 allele being associated with increased susceptibility to Alzheimer's disease, while the ε2 allele is linked to a reduced risk. 

Possessing the ε4 allele does not guarantee the development of Alzheimer's disease, nor does the absence of this allele rule out the possibility of developing the condition.

Additionally, the APOE genetic test does not provide a definitive diagnosis of Alzheimer's disease: rather, it offers valuable information for risk assessment and informing clinical management decisions such as lifestyle modifications and potential participation in clinical trials for disease-modifying therapies.

How Does the APOE4 Gene Confer Increased Risk of Alzheimer's Disease?  [8.]

The APOE4 allele confers an increased risk of Alzheimer's disease through several mechanisms. 

Firstly, the presence of the APOE4 allele is associated with higher levels of amyloid-beta deposition in the brain, which is a hallmark characteristic of Alzheimer's disease pathology.

 This allele may also contribute to impaired clearance of amyloid-beta from the brain, leading to its accumulation and the formation of plaques, which are toxic to neurons. 

APOE4 has been implicated in promoting neuroinflammation, oxidative stress, and altered lipid metabolism in the brain, which are processes involved in neuronal damage and degeneration. [10.]

Furthermore, APOE4 may affect synaptic plasticity and neuronal repair mechanisms, further exacerbating the neurodegenerative process. 

Conversely, the APOE2 gene is associated with a decreased risk of developing Alzheimer’s disease.

Individuals interested in testing their genes for the presence of APOE4 should consult with a healthcare professional to discuss the implications of genetic test results and implement an individualized plan.  

Order Genetic Testing for APOE4 

Click here to compare tests and order testing for the APOE4 gene.